Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eflornithine/sulindac - Cancer Prevention Pharmaceuticals

Drug Profile

Eflornithine/sulindac - Cancer Prevention Pharmaceuticals

Alternative Names: CPP-1X/sul; CPP-1X/sulindac; CPP1-x/sulindac; Sulindac/CPP-1X; Sulindac/eflornithine; TP 09

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Arizona; University of California at Irvine
  • Developer Cancer Prevention Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Basic amino acids; Diamino amino acids; Indenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Familial adenomatous polyposis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer; Familial adenomatous polyposis
  • Preclinical Pancreatic cancer

Most Recent Events

  • 07 May 2019 Mallinckrodt terminates its licence for eflornithine/sulindac in North America
  • 04 Dec 2018 Preclinical trials in Pancreatic cancer in USA (PO), before December 2018 (Cancer Prevention Pharmaceuticals pipeline, December 2018)
  • 04 Dec 2018 Cancer Prevention Pharmaceuticals plans a phase II/III trial for Pancreatic Cancer (Cancer Prevention Pharmaceuticals pipeline, December 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top